Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ADG206

Monoclonal antibody · Agonist of CD137 (TNFRSF9) · developed by Adagene

Phase 1 Most advanced trial
ADAG Developer
1 Registered trials

What is ADG206?

ADG206 is an Fc-enhanced IgG1 monoclonal antibody agonist of CD137 (4-1BB) covalently linked to a peptide mask that is selectively activated in the tumor microenvironment. It binds and activates CD137 on T-lymphocytes and natural killer cells, enhancing costimulatory signaling and promoting T-cell-mediated anti-tumor immune responses. It is studied in advanced and metastatic solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
CD137 (TNFRSF9)
Mechanism
Agonist of CD137 (TNFRSF9)
Pathways
T-cell proliferation, T-cell survival, cytokine production, anti-tumor immune responses
Therapy area
Oncology
Developer
Adagene Inc (ADAG)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05614258 Phase 1 Advanced/Metastatic Solid Tumors Active not recruiting ADAG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced/Metastatic Solid Tumors

Other drugs acting on TNFRSF9

Acasunlimab Phase 3 ADG106 Phase 1/2 AGEN2373 Phase 1/2 ALG.APV-527 Phase 1/2 CTX-471 Phase 1/2 Enristomig Phase 1

More from Adagene

ADG106 Phase 1/2 Firastotug Phase 1 Muzastotug Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ADAG page.

Follow ADAG, the company behind ADG206

See ADAG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADAG catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.